Project Grant R44HL182590
- This $321,679 Project Grant, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development and testing of an expandable pediatric pulmonary heart valve device. The research aims to create a valve that can grow larger with the patient to address the challenge of multiple open-heart surgeries required for infants and children with severe heart valve defects. The key research activities include optimizing the...
- This Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a modern Electrical Impedance Tomography (EIT) device for monitoring children in the Intensive Care Unit (ICU). The $299,900 award to Goodlife Inventors LLC will fund efforts to (1) generate initial designs for an advanced lightweight EIT belt and (2) assess the technical feasibility of a miniaturized, easier to use EIT core device. If...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is funding the development of a "Fail Safe, High Output Failing Fontan Pump" to provide mechanical circulatory support for individuals with congenital heart disease and single ventricle physiology. The $320,838 award to Perfusion Solutions Inc. (UEI: TF8CUC65VLG5) supports the hydraulic design refinement and component development of a...
- The $784,203 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is supporting the development and testing of a small, durable, and hemocompatible centrifugal blood pump for use in children aged 1-11 years (weighing approximately 10-35 kg) with heart failure. The immediate goal is to test and refine the "PSU Child VAD" (ventricular assist device) prototype through a series of 30-day in-vivo studies to validate the design...
- This Project Grant award from the National Heart, Lung, and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a bearingless flux reversal motor for a neonatal and pediatric extracorporeal life support application. The $870,467 award to Ension Inc. aims to address shortcomings of the currently available pediatric blood pump, the Abbott Pedimag, by developing an innovative bearingless (magnetically levitated) motor...
- This $499,103 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports Alleviant Medical, Inc. in two key efforts: Implementing high-volume manufacturing capabilities and establishing production readiness for the ALV1 system, a novel transcatheter approach to relieve left atrial pressure in heart failure patients without requiring a cardiac implant. Executing reimbursement and marketing initiatives to...
- Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...
- This federal Project Grant award from the National Heart Lung and Blood Institute under CFDA Program 93.837 - Cardiovascular Diseases Research provides $306,872 to Airalux Medical, Inc. to develop a digital incentive spirometry device. The goal is to improve patient adherence and clinical workflows for preventing post-surgical lung complications, which occur in 1 in 20 patients undergoing an overnight hospital stay. The device uses sensors and software to automatically track patient usage and...
- This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...
This Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), funds the development of Heartpoint Global's IntelliSent - a minimally invasive, adjustable pulmonary flow restrictor system for pediatric and congenital heart disease patients. The $1,771,084 award supports efforts to (1) downsize the IntelliSent device to be suitable for patients from birth, including preclinical testing, (2) complete biocompatibility testing for regulatory submission, and (3) optimize manufacturing processes for clinical and commercial production. Successful completion of this project would bring to market a novel treatment for modifying pulmonary flow in pediatric patients with congenital and acquired heart conditions, representing a transformative advancement in this medical field.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.8m | 8/22/25 |